Search results for "Neoplasm Metastasi"

showing 10 items of 288 documents

Quality analysis of population-based information on cancer stage at diagnosis across Europe, with presentation of stage-specific cancer survival esti…

2017

Abstract Background Cancer registries (CRs) are fundamental for estimating cancer burden, evaluating screening and monitoring health service performance. Stage at diagnosis—an essential information item collected by CRs—has been made available, for the first time, by CRs participating in EUROCARE-5. We analysed the quality of this information and estimated stage-specific survival across Europe for CRs with good data quality. Data and methods Sixty-two CRs sent stage (as TNM, condensed TNM or extent of disease) for 15 cancers diagnosed in 2000–2007. We assessed the quality, partly by comparing stage according to the three systems. We also developed procedures to reconstruct stage (categories…

Malemedicine.medical_specialtyCancer ResearchStage at diagnosiSurvivalConcordanceCancer registrieCancer registries ; Data quality ; Stage at diagnosis ; SurvivalSocio-culturaleReproducibility of ResultPredictive Value of TestCancer registries; Data quality; Stage at diagnosis; Survival; Data Accuracy; Europe; Female; Humans; Male; Neoplasm Metastasis; Neoplasms; Predictive Value of Tests; Reproducibility of Results; Survival Analysis; Neoplasm Staging; Registries; Oncology; Cancer Research03 medical and health sciences0302 clinical medicineBreast cancerPredictive Value of TestsNeoplasmsmedicineotorhinolaryngologic diseasesCancer registriesHumans030212 general & internal medicineRegistriesStage (cooking)Neoplasm MetastasisIntensive care medicineSurvival analysisCancer stagingNeoplasm Stagingbusiness.industryData qualityReproducibility of ResultsStage at diagnosismedicine.diseaseSurvival AnalysisCancer registryData AccuracyClinical trialNeoplasm MetastasiEuropeOncology030220 oncology & carcinogenesisData qualityNeoplasmFemaleSurvival AnalysibusinessHumanEuropean journal of cancer (Oxford, England : 1990)
researchProduct

Organ recipients suffering from undifferentiated neuroendocrine small-cell carcinoma of donor origin: a case report.

2009

Abstract Background Transmission of donor-derived cancer by organ transplantation is rare, but the risk has been increasing due to the aging donor pool. Undifferentiated neuroendocrine small-cell carcinoma is an agressive tumor with the tendency to spread. Herein we have demonstrated different approaches to treat organ recipients with transmitted tumors. Methods and Results Grafts were retrieved from a decreased donor without any history of previous diseases. Autopsy was not performed after donation. The recipient of the liver graft presented with suspected nodules on routine abdominal ultrasound. After computed tomography (CT) scan, biopsy confirmed the diagnosis of a small-cell carcinoma.…

Malemedicine.medical_specialtyCarcinoma Hepatocellularmedicine.medical_treatmentAutopsyAntineoplastic AgentsSmall-cell carcinomaNephrectomyOrgan transplantationCarboplatinalpha 1-Antitrypsin DeficiencyBiopsymedicineCarcinomaHumansCarcinoma Small CellNeoplasm MetastasisEtoposideTransplantationChemotherapymedicine.diagnostic_testbusiness.industryLiver NeoplasmsCancerMiddle Agedmedicine.diseaseDNA FingerprintingEmbolization TherapeuticKidney TransplantationTissue DonorsSurgeryLiver TransplantationTransplantationHeart TransplantationSurgerybusinessImmunosuppressive AgentsTransplantation proceedings
researchProduct

Secondary technical resectability of colorectal cancer liver metastases after chemotherapy with or without selective internal radiotherapy in the ran…

2019

Background: Secondary resection of initially unresectable colorectal cancer liver metastases (CRLM) can prolong survival. The added value of selective internal radiotherapy (SIRT) to downsize lesions for resection is not known. This study evaluated the change in technical resectability of CRLM with the addition of SIRT to FOLFOX-based chemotherapy. Methods: Baseline and follow-up hepatic imaging of patients who received modified FOLFOX (mFOLFOX6: fluorouracil, leucovorin, oxaliplatin) chemotherapy with or without bevacizumab (control arm) versus mFOLFOX6 (with or without bevacizumab) plus SIRT using yttrium-90 resin microspheres (SIRT arm) in the phase III SIRFLOX trial were reviewed by thr…

Malemedicine.medical_specialtyTime FactorsHepatic resectionTreatment outcomeAntineoplastic Agents030230 surgeryMicrosphereClinical study03 medical and health sciences0302 clinical medicinemedicineHepatectomyHumansNeoplasm MetastasisChirurgieLiver imagingRetrospective Studiesbusiness.industryIndividual participant dataLiver NeoplasmsFollow up studiesPatient dataOriginal ArticlesMiddle AgedTreatment Outcome030220 oncology & carcinogenesisFamily medicineHPBLower GISurgeryOriginal ArticleFemaleRadiotherapy AdjuvantbusinessColorectal NeoplasmsTomography X-Ray Computed:Ciencias de la Salud::Oncología [Materias Investigacion]Follow-Up Studies
researchProduct

Prediction of Normal Organ Absorbed Doses for [177Lu]Lu-PSMA-617 Using [44Sc]Sc-PSMA-617 Pharmacokinetics in Patients With Metastatic Castration Resi…

2018

In vivo pharmacokinetic analysis of [Sc]Sc-PSMA-617 was used to determine the normal organ-absorbed doses that may result from therapeutic activity of [Lu]Lu-PSMA-617 and to predict the maximum permissible activity of [Lu]Lu-PSMA-617 for patients with metastatic castration-resistant prostate carcinoma. Methods Pharmacokinetics of [Sc]Sc-PSMA-617 was evaluated in 5 patients with metastatic castration-resistant prostate carcinoma using dynamic PET/CT, followed by 3 static PET/CT acquisitions and blood sample collection over 19.5 hours, as well as urine sample collection at 2 time points. Total activity measured in source organs by PET imaging, as well as counts per milliliter measured in bloo…

Malemedicine.medical_treatmentUrineLutetiumRadiation Dosageurologic and male genital diseases030218 nuclear medicine & medical imagingCastration-Resistant Prostate CarcinomaHeterocyclic Compounds 1-Ring03 medical and health sciences0302 clinical medicinePharmacokineticsIn vivoPositron Emission Tomography Computed TomographyOrganometallic CompoundsmedicineHumansRadiology Nuclear Medicine and imagingExternal beam radiotherapyNeoplasm MetastasisAgedUrinary bladderbusiness.industryRadiotherapy Planning Computer-AssistedCarcinomaRadiotherapy DosageDipeptidesGeneral MedicineProstate-Specific AntigenProstatic Neoplasms Castration-Resistantmedicine.anatomical_structure030220 oncology & carcinogenesisSample collectionBone marrowRadiopharmaceuticalsbusinessNuclear medicineScandiumClinical Nuclear Medicine
researchProduct

Characterization of C4-2 Prostate Cancer Bone Metastases and Their Response to Castration

2003

New well-characterized preclinical models of prostate cancer (CaP) bone metastases are needed to improve our understanding of the development of CaP-related bone disease in patients. Here we describe characterization of a model consisting of direct injection of C4–2 cells into tibias. Introduction: Prostate cancer (CaP) has a high proclivity to metastasize to bone. Development and characterization of preclinical models of CaP bone metastases are of high interest. The objective of this study was to characterize C4–2 bone metastases and their response to castration. Materials and Methods: Cell suspensions of C4-2, a subline of LNCaP, were injected directly into the tibias of intact male mice.…

Malemusculoskeletal diseasesmedicine.medical_specialtyTime FactorsBone densityBone diseaseEndocrinology Diabetes and MetabolismLong boneMice SCIDBone and BonesMicechemistry.chemical_compoundProstate cancerBone DensityCell Line TumorInternal medicineBone cellmedicineAnimalsHumansOrthopedics and Sports MedicineCastrationNeoplasm MetastasisBone mineralTibiabusiness.industryProstatic NeoplasmsBone metastasisProstate-Specific Antigenmusculoskeletal systemmedicine.diseaseCastrationmedicine.anatomical_structureEndocrinologychemistryReceptors AndrogenbusinessNeoplasm TransplantationJournal of Bone and Mineral Research
researchProduct

Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer.

2017

Biological changes that occur during metastatic progression of breast cancer are still incompletely characterized. In this study, we compared intrinsic molecular subtypes and gene expression in 123 paired primary and metastatic tissues from breast cancer patients. Intrinsic subtype was identified using a PAM50 classifier and χ2 tests determined the differences in variable distribution. The rate of subtype conversion was 0% in basal-like tumors, 23.1% in HER2-enriched (HER2-E) tumors, 30.0% in luminal B tumors, and 55.3% in luminal A tumors. In 40.2% of cases, luminal A tumors converted to luminal B tumors, whereas in 14.3% of cases luminal A and B tumors converted to HER2-E tumors. We ident…

Mama -- Càncer -- Aspectes genètics0301 basic medicineCancer ResearchPathologyReceptor ErbB-2DiseaseTranscriptome0302 clinical medicineGene expressionSurvival outcomes Letrozole Concordance Predictor Disease Impact Brain Cells Women RiskSurvival outcomesDiseaseNeoplasm Metastasisskin and connective tissue diseasesRegulation of gene expressionAged 80 and overBrainCells WomenMiddle AgedPrognosisMetastatic breast cancerNeoplasm ProteinsGene Expression Regulation NeoplasticImpactOncology030220 oncology & carcinogenesisLetrozoleFemaleRiskAdultmedicine.medical_specialtymedicine.drug_classBreast NeoplasmsBiologyArticle03 medical and health sciencesBreast cancerConcordancemedicineBiomarkers TumorHumansGeneAgedEstrogensmedicine.disease030104 developmental biologyEstrogenNeoplasm Recurrence LocalTranscriptomePredictor
researchProduct

Combination chemotherapy with mitomycin C, vindesine and melphalan for refractory metastatic breast cancer.

1991

A combination of mitomycin C, vindesine and melphalan was administered to 33 patients with heavily pretreated refractory breast cancer. The overall response rate was 27% with a mean duration of more than 10.2 months. A stabilization with a mean duration of 5.1 months was seen in 56% of cases, while 20% of patients progressed. Gastrointestinal toxicity, mostly grade 1 or 2 nausea/vomiting was seen in 85% of cases, grade 1 or 2 leukopenia in 60% of patients, and grade 1 or 2 thrombocytopenia in 42%. Considering the good compliance of this regimen and the poor prognosis of patients with refractory advanced breast cancer, this combination can be useful as a palliative treatment of breast carcin…

MelphalanOncologyAdultCancer Researchmedicine.medical_specialtyVindesinemedicine.medical_treatmentMitomycinBreast NeoplasmsMitomycinsBreast cancerInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansNeoplasm MetastasisMelphalanAgedChemotherapybusiness.industryMitomycin CPalliative CareCancerCombination chemotherapyGeneral MedicineMiddle Agedmedicine.diseaseMetastatic breast cancerOncologyVindesineFemalebusinessmedicine.drugJournal of cancer research and clinical oncology
researchProduct

Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy

2014

International audience; The immune system is routinely confronted with cell death resulting from the physiological turnover of renewable tissues, as well as from pathological insults of several types. We hypothesize the existence of a mechanism that allows the immune system to discriminate between physiological and pathological instances of cell death, but the factors that determine whether cellular demise is perceived as a neutral, tolerogenic or immunogenic event remain unclear 1. Infectious insults are accompanied by so-called microbe-associated molecular patterns (MAMPs), i.e., viral or bacterial products that activate immune cells through a panel of pattern-recognition receptors (PRRs)…

Myxovirus Resistance ProteinsMessengerReceptor Interferon alpha-betaInbred C57BLchemotherapyInterferon alpha-betaMiceInterferonReceptorsAnthracyclinesNeoplasm MetastasisRIG-IPattern recognition receptorAdaptor ProteinsGeneral MedicineNeoadjuvant Therapy3. Good healthGene Expression Regulation NeoplasticTreatment OutcomeReceptors Pattern RecognitionInterferon Type I[SDV.IMM]Life Sciences [q-bio]/ImmunologyFemaleImmunocompetencemedicine.drugReceptorSignal TransductionBreast Neoplasms[SDV.CAN]Life Sciences [q-bio]/CancerBiologyPattern RecognitionSettore BIO/09General Biochemistry Genetics and Molecular BiologyParacrine signallingImmune systemmedicineCXCL10AnimalsHumanscancerRNA MessengerAutocrine signallingNeoplastic[SDV.IMM.IMM]Life Sciences [q-bio]/Immunology/ImmunotherapyToll-Like Receptor 3Mice Inbred C57BLVesicular TransportChemokine CXCL10Adaptor Proteins Vesicular TransportGene Expression RegulationDoxorubicinImmunologyTLR3RNAAdaptor Proteins Vesicular Transport; Animals; Anthracyclines; Breast Neoplasms; Chemokine CXCL10; Doxorubicin; Female; Gene Expression Regulation Neoplastic; Humans; Immunocompetence; Interferon Type I; Mice Inbred C57BL; Myxovirus Resistance Proteins; Neoadjuvant Therapy; Neoplasm Metastasis; RNA; RNA Messenger; Receptor Interferon alpha-beta; Receptors Pattern Recognition; Toll-Like Receptor 3; Treatment Outcome; Signal Transduction
researchProduct

Extrahepatic spread of hepatocellular carcinoma

2012

Hepatocellular carcinoma (HCC) is a major health problem. The treatment of HCC depends on the tumour stage and on the severity of underlying cirrhosis, however, a majority of HCC patients have advanced disease at presentation. In recent years extra-hepatic spread (ES) of HCC seems to have been observed more frequently than in the past even if few data exist in literature on prevalence, clinical presentation and prognosis of patients with HCC ES. Aim of this brief review is underline the main concerns, pitfalls and warnings in practicing with these patients. ES of HCC are not rare, and the probability of finding ES is higher in patients with advanced intra-hepatic HCC. The more frequent ES s…

NiacinamideSettore MED/12 - GastroenterologiaCarcinoma HepatocellularPhenylurea CompoundsLiver NeoplasmsCarcinomaCarcinoma; Hepatocellular; Neoplasm metastasis; sorafenibAntineoplastic AgentsHepatocellularPrognosisSettore MED/28 - Malattie OdontostomatologicheAnimalsHumansNeoplasm InvasivenesssorafenibMolecular Targeted TherapyProtein Kinase InhibitorsNeoplasm metastasi
researchProduct

The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Pro…

2017

Abstract Background The androgen receptor splice variant 7 (AR-V7) is associated with resistance to hormonal therapy in castration-resistant prostate cancer (CRPC). Due to limitations of the methods available for AR-V7 analysis, the identification of a reliable detection method may facilitate the use of this biomarker in clinical practice. Objective To confirm AR-V7 as a predictor of resistance to hormonal therapy and develop a new approach to assess AR-V7 by highly sensitive digital droplet polymerase chain reaction (ddPCR) in plasma-derived exosomal RNA. Design, setting, and participants Plasma samples were collected from 36 CRPC patients before they began second-line hormonal treatment. …

Oncology0301 basic medicineMaleResistanceExosomeschemistry.chemical_compoundProstate cancer0302 clinical medicineProtein IsoformsNeoplasm MetastasisReceptorAged 80 and overProstate cancerMiddle AgedProstatic Neoplasms Castration-ResistantReceptors Androgen030220 oncology & carcinogenesisBenzamidesAdenocarcinomaBiomarker (medicine)Hormonal therapyAR-V7; Digital droplet PCR; Exosomes; Hormonal therapy; Pharmacogenetics; Prostate cancer; Resistance; UrologyAndrostenesHormonal therapymedicine.medical_specialtyAntineoplastic Agents Hormonalmedicine.drug_classUrologyCastration resistantAdenocarcinomaDisease-Free Survival03 medical and health sciencesSDG 3 - Good Health and Well-beingInternal medicineNitrilesPhenylthiohydantoinmedicineEnzalutamideHumansAgedDigital droplet PCRPlasma derivedbusiness.industryRNAAndrogen Receptor Splice Variant 7medicine.diseaseAndrogenEndocrinology030104 developmental biologychemistryPharmacogeneticsDrug Resistance NeoplasmCancer cellCancer researchRNAAR-V7businessPharmacogenetics
researchProduct